Glycotope Receives Regulatory Approval for GlycoExpress Technology and Initiates First Clinical Trial with Lead Antibody GT-MAB 2.5 GEX - Pharmaceutical Business review
Glycotope Receives Regulatory Approval for GlycoExpress Technology and Initiates First Clinical Trial with Lead Antibody GT-MAB 2.5 GEX
Share
SEND TO A COLLEAGUE
The approvals further underline the suitability of Glycotope’s proprietary GlycoExpress technology for the improvement, glycooptimisation and high yield production of therapeutic proteins for the use in humans.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
